Lithium Orotate/Orotic acid lithium salt monohydrate

Lithium Orotate (Orotic Acid Lithium Salt Monohydrate, CAS 5266-20-6) – High-Purity Neuroprotective Compound for Alzheimer’s Research & Therapeutic Development. Backed by Harvard’s 2025 Nature study, this compound targets brain lithium deficiency (a key Alzheimer’s driver) by avoiding beta-amyloid binding, preserving neuroprotective efficacy. Preclinically proven to reverse memory loss and neuronal damage in AD-model mice (ultra-low dose effective). We supply high-quality, consistent-grade lithium orotate to support your research, drug development, or commercial applications.

High-Quality Lithium Orotate (CAS 5266-20-6) – Trusted Supplier for Alzheimer’s Therapeutic Research. As a specialized lithium salt, it solves a critical limitation of conventional lithium forms: non-binding to beta-amyloid, ensuring optimal bioavailability to replenish brain lithium levels. Validated by Harvard’s landmark study to reverse AD progression in preclinical models. We offer reliable bulk supply, strict quality control (purity ≥99%), and technical support to meet your R&D or production needs.

Lithium Orotate (CAS 5266-20-6) – Your Preferred Source for Alzheimer’s-Focused Compounds. This neuroprotective lithium salt is scientifically proven (Harvard/Nature) to target the root cause of Alzheimer’s (brain lithium depletion), with preclinical data showing memory restoration and neurodegeneration reversal. We provide cost-effective, high-purity supplies (customizable quantities) for pharmaceutical R&D, academic research, and therapeutic product manufacturing. Fast delivery, consistent quality, and professional after-sales support.